Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    BioXcel Therapeutics Inc.

    NASDAQ: BTAI · Real-Time Price · USD
    1.54
    0.01 (0.65%)
    At close: Jun 05, 2025, 3:59 PM
    1.50
    -2.60%
    After-hours: Jun 05, 2025, 07:00 PM EDT

    BioXcel Therapeutics Statistics

    Share Statistics

    BioXcel Therapeutics has 6.06M shares outstanding. The number of shares has increased by 39.15% in one year.

    Shares Outstanding

    n/a
    		 6.06M

    Shares Change (YoY)

    n/a
    		 39.15%

    Shares Change (QoQ)

    n/a
    		 5.23%

    Owned by Institutions (%)

    n/a
    		 1.26%

    Shares Floating

    n/a
    		 n/a

    Failed to Deliver (FTD) Shares

    n/a
    		 39,700

    FTD / Avg. Volume

    n/a
    		 9.98%

    Short Selling Information

    The latest short interest is 133.79K, so 2.21% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 133.79K

    Short % of Shares Out

    n/a
    		 2.21%

    Short % of Float

    n/a
    		 2.41%

    Short Ratio (days to cover)

    n/a
    		 1.13

    Valuation Ratios

    The PE ratio is -0.25 and the forward PE ratio is -0.13. BioXcel Therapeutics's PEG ratio is 0.

    PE Ratio

    n/a
    		 -0.25

    Forward PE

    n/a
    		 -0.13

    PS Ratio

    n/a
    		 6.69

    Forward PS

    n/a
    		 0

    PB Ratio

    n/a
    		 -0.16

    P/FCF Ratio

    n/a
    		 -0.21

    PEG Ratio

    n/a
    		 0
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for BioXcel Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 1.68, with a Debt / Equity ratio of -1.11.

    Current Ratio

    n/a
    		 1.68

    Quick Ratio

    n/a
    		 1.65

    Debt / Equity

    n/a
    		 -1.11

    Debt / EBITDA

    n/a
    		 -2.33

    Debt / FCF

    n/a
    		 -1.43

    Interest Coverage

    n/a
    		 -4.44

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $61,243.24

    Profits Per Employee

    n/a
    		 $-1,610,783.78

    Employee Count

    n/a
    		 37

    Asset Turnover

    n/a
    		 0.06

    Inventory Turnover

    n/a
    		 3.16

    Taxes

    Income Tax

    n/a
    		 n/a

    Effective Tax Rate

    n/a
    		 0%

    Stock Price Statistics

    The stock price has increased by -94.1% in the last 52 weeks. The beta is -0.13, so BioXcel Therapeutics's price volatility has been lower than the market average.

    Beta

    n/a
    		 -0.13

    52-Week Price Change

    n/a
    		 -94.1%

    50-Day Moving Average

    n/a
    		 1.67

    200-Day Moving Average

    n/a
    		 5.68

    Relative Strength Index (RSI)

    n/a
    		 51.64

    Average Volume (20 Days)

    n/a
    		 397,895

    Income Statement

    In the last 12 months, BioXcel Therapeutics had revenue of 2.27M and earned -59.6M in profits. Earnings per share was -23.51.

    Revenue

    n/a
    		 2.27M

    Gross Profit

    n/a
    		 123K

    Operating Income

    n/a
    		 -67.25M

    Net Income

    n/a
    		 -59.6M

    EBITDA

    n/a
    		 -44.16M

    EBIT

    n/a
    		 -44.47M

    Earnings Per Share (EPS)

    n/a
    		 -23.51
    Full Income Statement

    Balance Sheet

    The company has 29.85M in cash and 102.95M in debt, giving a net cash position of -73.09M.

    Cash & Cash Equivalents

    n/a
    		 29.85M

    Total Debt

    n/a
    		 102.95M

    Net Cash

    n/a
    		 -73.09M

    Retained Earnings

    n/a
    		 -650.2M

    Total Assets

    n/a
    		 38.57M

    Working Capital

    n/a
    		 12.23M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -72.03M and capital expenditures 0, giving a free cash flow of -72.03M.

    Operating Cash Flow

    n/a
    		 -72.03M

    Capital Expenditures

    n/a
    		 n/a

    Free Cash Flow

    n/a
    		 -72.03M

    FCF Per Share

    n/a
    		 -28.41
    Full Cash Flow Statement

    Margins

    Gross margin is 5.43%, with operating and profit margins of -2967.56% and -2630.14%.

    Gross Margin

    n/a
    		 5.43%

    Operating Margin

    n/a
    		 -2967.56%

    Pretax Margin

    n/a
    		 -2630.14%

    Profit Margin

    n/a
    		 -2630.14%

    EBITDA Margin

    n/a
    		 -1948.85%

    EBIT Margin

    n/a
    		 -2967.56%

    FCF Margin

    n/a
    		 -3178.6%

    Dividends & Yields

    BTAI does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for BTAI is $48, which is 3016.9% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $48

    Price Target Difference

    n/a
    		 3016.9%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 5
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Stock Splits

    The last stock split was on Feb 10, 2025. It was a backward split with a ratio of 1:16.

    Last Split Date

    n/a
    		 Feb 10, 2025

    Split Type

    n/a
    		 backward

    Split Ratio

    n/a
    		 1:16

    Scores

    Altman Z-Score

    n/a
    		 -25.84

    Piotroski F-Score

    n/a
    		 3

    Add to Watchlist